A founder of a Series D SaaS company with a $800M valuation dies unexpectedly. Her estate includes 50,000 shares of restricted common stock, 100,000 unvested options at $0.25/share, and 2 SAFEs from seed rounds. The company shows no signs of going public or being acquired. The executor opens the option plan documents and discovers vesting acceleration only triggers on an "acquisition" defined narrowly as a purchase price above $50M. There is no secondary market for the startup's shares. The executor is now locked into a multi-year holding pattern, unable to generate liquidity and facing estate tax liability on shares with little probability of becoming worth anything.
This scenario plays out regularly enough that any practitioner handling founder estates must understand the mechanics of illiquid startup equity. The challenge is not theoretical. Founders accumulate substantial equity positions but often lack basic documentation about vesting terms, acceleration provisions, secondary market options, and tax treatment. Executors inherit both the assets and the uncertainty.
The Illiquidity Problem in Founder Estates
Illiquid equity creates cascading problems for executors. Most startup shares are restricted under company operating agreements or shareholder agreements. There is no public market. There is no formula for converting them to cash on a defined timeline. This stands in sharp contrast to founder estates from prior generations, where primary assets were real estate, publicly traded securities, or established businesses with clear valuation methods.
Illiquidity creates a valuation discount. Under IRC §409A, companies must obtain annual independent appraisals of their common stock. These valuations apply the "Discount for Lack of Marketability" (DLOM), typically 40-60%, to account for the absence of a liquid market. A Series D startup with a $100M post-money valuation might show founder common shares valued at $0.15 to $0.50 per share for tax purposes. The same shares might have possessed theoretical value of $2-$3 per share in a liquid market.
This creates immediate friction: the estate faces tax liability based on the high-end valuation (which the IRS prefers for estate tax purposes), but cannot actually realize that value when selling. An estate with $2M in restricted founder shares might owe $800,000 in estate tax while being unable to generate more than $600,000-$800,000 in proceeds from a secondary market sale.
The risk profile adds another dimension. Shares in a pre-exit startup have no floor. If the company fails, the shares become worthless. QSBS benefits under IRC §1045, which allow founders to exclude gains on certain startup shares from capital gains tax, expire if not exercised during the founder's lifetime. An executor cannot resurrect these benefits. The estate loses the benefit entirely.
The executor faces a genuine dilemma: hold the shares in perpetuity hoping for eventual liquidity, or sell at a steep discount to secondary market buyers who demand 30-50% haircuts for the illiquidity and risk they are absorbing. Holding locks capital in non-productive assets. Selling realizes immediate losses and concedes upside potential, however unlikely.
Equity Instruments in Tech Startups: Options, Restricted Stock, and SAFEs
Startup founders hold several categories of equity. Understanding the contractual terms governing each is essential before any settlement strategy can be formulated.
Stock options, both Incentive Stock Options (ISOs) under IRC §422 and Non-Qualified Stock Options (NSOs) under IRC §83, are the most common founder equity. ISOs receive favorable tax treatment if held long enough. NSOs are taxed as ordinary income when exercised, but offer more flexibility. The option plan documents specify a vesting schedule, typically a four-year vest with a one-year cliff. This means no shares vest until one year of service, then shares vest monthly or quarterly. If a founder dies before vesting, the unvested portion typically lapses unless the plan specifies otherwise.
Vesting acceleration upon death is a critical contract provision. Some plans include single-trigger acceleration, meaning all unvested options vest automatically when the founder dies. Others use double-trigger acceleration, requiring both death and subsequent termination of employment. Some plans include no acceleration at all. This difference can be worth hundreds of thousands of dollars. The executor must obtain the actual option plan documents and read the acceleration language carefully. Email confirmations or company communications are insufficient. The plan document controls.
SAFEs (Simple Agreements for Future Equity) complicate founder estates substantially. A SAFE is a convertible instrument that converts into equity at a future financing event or acquisition. It specifies a discount rate (e.g., 20% discount on next funding round) and a valuation cap. SAFEs have no specified exit date and no guaranteed conversion. If a company remains private indefinitely, a SAFE remains unconverted. The estate must hold the SAFE indefinitely or attempt to sell it on secondary markets at deep discounts reflecting the uncertainty.
Valuating SAFEs at death is problematic. They have no fixed strike price like options. Their value depends on assumptions about future financing rounds, discount rates applied, and probability of conversion within reasonable timeframes. An independent appraiser must make these judgments. The resulting valuation is highly speculative and vulnerable to challenge by the IRS if perceived as understated.
Restricted Stock Units (RSUs) represent another common grant structure. RSUs vest over time and convert to shares upon vesting. Unvested RSUs typically lapse on death unless the plan specifies acceleration. Some plans allow earned RSUs to be paid out in cash. The specific plan documents determine whether an RSU estate asset has value.
409A Valuations and the Executor's Tax Basis Problem
The 409A valuation, prepared annually by an independent appraiser, serves as the deemed fair market value of common stock for federal tax purposes. This valuation is critical but misunderstood by many executors.
The 409A process involves applying a standard valuation methodology (income, market, or asset approach) and then applying DLOM. The DLOM reflects the lack of a liquid market for the shares. A 40-60% DLOM is common for early-stage startups. The result is a per-share value significantly lower than the implied per-share value in the most recent financing round. A $100M Series B on a $500M post-money valuation implies approximately $5 per share of fully diluted common, but the 409A value might be $1.50 per share after applying the DLOM.
A critical timing issue: if the most recent 409A valuation was completed months before the founder's death, the shares must be revalued as of the date of death. The executor cannot simply use the most recent 409A. If the startup has experienced significant changes (new financing, major customer loss, competitive pressure), the post-death valuation could be substantially different. A fresh appraisal by an independent valuer is required. This adds cost (typically $3,000-$8,000) and timeline delays (4-8 weeks), but it is necessary for estate tax filing.
The 409A value becomes the FMV for estate tax purposes and determines the probate estate's reported value. This is where the executor encounters a cruel mathematics problem. Suppose the founder held 50,000 shares. The 409A value is $1.00/share. Estate tax basis is $50,000. But the secondary market buyer will offer only $0.50/share ($25,000). The estate pays estate tax on $50,000 worth of assets but realizes only $25,000 in proceeds.
The executor should understand IRC §1014 step-up in basis rules. When an asset passes through an estate, the beneficiary's basis resets to fair market value on the date of death. The original founder's strike price is irrelevant for basis purposes. If the founder purchased stock at $0.01/share and it was valued at $1.00/share at death, the heir's basis is $1.00/share. This rule applies to all equity, whether options, restricted stock, or SAFEs. It is one of the few favorable provisions in the tax code for inherited assets.
Secondary Market Sales and Liquidity Options
Secondary markets for startup equity have matured significantly since 2015. Platforms including EquityZen, Carta, SharePost, and Forge (now a public company) facilitate transactions between sellers and buyers. These markets have enabled executors to realize at least partial liquidity on illiquid founder shares.
Secondary market pricing is substantially below the most recent 409A valuation. Buyers demand significant discounts for illiquidity, regulatory risk, and the time value of money. A common range is 20-50% below the latest 409A valuation. Selling a $1M position valued at $1.00/share will likely net $400,000-$600,000 after transaction costs. The discount reflects the buyer's assessment of the probability of a successful exit within a reasonable timeframe and the risks of total loss.
Secondary sale mechanics are cumbersome. The startup must consent to the transfer, as most shareholder agreements include transfer restrictions. The process requires coordination between the executor, the secondary market platform, company counsel, and potentially investor consent. Timeline is typically 8-12 weeks from initiation to close. Transaction costs run 5-10%, which is substantial on smaller sales.
SAFEs and options are even more problematic on secondary markets. SAFEs are heavily discounted because their conversion is speculative. Options are rarely traded on secondary markets unless the startup is near an exit, at which point the option holders often convert or exercise directly. An executor holding NSOs in a pre-exit startup will find minimal secondary market demand.
Some startups conduct tender offers, allowing founders and employees to sell shares directly back to the company. These are not guaranteed, depend on company cash flow and board authorization, and are typically offered at discounts to recent fundraising valuations. A tender offer at 50% of the 409A valuation might be the best available exit, however.
For executors managing founder estates, secondary sale proceeds should be modeled conservatively. Assume 30-40% haircuts from the 409A valuation and assume 3-4 month execution timelines. Build these assumptions into the estate settlement plan and cash flow projections.
Tax Implications of Founder Equity at Death
The tax treatment of founder equity at death depends on the equity category and the founder's prior actions.
ISOs versus NSOs receive different tax treatment. ISOs are taxed as ordinary income when exercised only to the extent the exercise price is below fair market value at exercise. The difference between FMV and strike price (the "bargain element") is ordinary income. Gains above FMV at exercise receive capital gains treatment if the founder held the stock long enough (two years from grant, one year from exercise). NSOs are taxed as ordinary income when exercised based on the spread between FMV and strike price.
The executor who exercises founder ISOs can accidentally trigger NSO treatment. If the executor exercises ISOs after the founder's death, the bargain element is taxable income to the estate. If the executor does not pay the tax promptly, the tax basis becomes compromised and capital gains treatment may not apply. This is a technical trap. The executor should consult with tax counsel before exercising any ISOs, particularly if the option grant was recent.
AMT (Alternative Minimum Tax) is a significant risk if the founder exercised ISOs in the year of death or shortly before death. The bargain element on ISO exercise is an AMT adjustment. If AMT is greater than regular income tax, AMT applies. The founder may have already paid AMT in the year of death; the executor needs to determine this from the final tax return.
If the startup is acquired after the founder's death and the acquisition eliminates founder common equity, the tax treatment depends on the deal structure. If the equity receives no consideration, it is a capital loss to the estate. If the equity receives consideration but is below the founder's original cost basis, the loss may still be deductible. If the equity receives consideration above the date-of-death valuation, the appreciation is capital gain. The executor should work with the company's tax counsel to understand how the acquisition agreement treats founder common equity.
Estate Planning Recommendations for Founders
While the article is addressed to executors navigating founder estates, a brief note on preventive planning is warranted, as some founders reading this may still be living.
Founders should exercise stock options proactively during their lifetimes if the exercises are economically feasible. Exercising locks in the current strike price and tax treatment. It eliminates the risk that the executor must exercise options under unfavorable circumstances or face AMT traps. For NSOs, early exercise followed by a Section 83(b) election locks in capital gains treatment and starts the holding period for favorable capital gains tax rate. For ISOs, early exercise captures the bargain element now rather than deferring the tax burden to the estate.
Founders should also consider secondary sales of a portion of their founder shares during their lifetime if secondary market opportunities are available. Selling even 10-20% of a founder's equity stake during a favorable secondary market window reduces the concentration risk and illiquidity problem passed to the estate.
Documenting all equity is critical. Founders often forget about SAFEs issued in seed rounds, options granted from multiple companies, or grants structured as restricted stock purchases. Creating an equity schedule with grant dates, vesting schedules, strike prices, and acceleration provisions provides the executor with essential information. Without documentation, valuable rights may be overlooked or may lapse.
FAQ
Q: What happens to a founder's stock options when they die?
Stock options vest according to the terms in the company's option plan. If the plan includes acceleration triggered by death, all unvested options typically vest immediately. If not, unvested options lapse and are forfeited. The executor must obtain the option plan documents to determine what acceleration provisions exist. The vesting schedule in the option agreement is legally binding and cannot be modified retroactively. Some plans are more generous than others; a single-trigger acceleration provision can be worth hundreds of thousands of dollars.
Q: How are founder shares valued for estate tax purposes?
Founder shares are valued based on an annual 409A valuation prepared by an independent appraiser. The valuation applies the Company's valuation methodology (typically a combination of income, market, and asset approaches) and applies a discount for lack of marketability (DLOM) of 40-60%. The resulting per-share value is the fair market value used for estate tax filing. If the most recent 409A valuation is more than a few months old, a fresh appraisal as of the date of death is required. The 409A value often does not match the implied per-share value from recent financing rounds because of the DLOM.
Q: Can founder shares be sold on secondary markets?
Yes, but at substantial discounts. Secondary market platforms including EquityZen, Carta, SharePost, and Forge facilitate transactions in private company equity. Prices are typically 20-50% below the most recent 409A valuation, reflecting buyer demand for discounts due to illiquidity and risk. The sale process requires company consent (most shareholder agreements restrict transfers), takes 8-12 weeks, and involves transaction costs of 5-10%. Secondary markets work best for shares in late-stage startups approaching exits. Early-stage equity finds fewer buyers.
Q: What is a SAFE and what happens to it when the founder dies?
A SAFE (Simple Agreement for Future Equity) is a convertible instrument that converts into equity when the company raises a future financing round or is acquired. SAFEs have no specified exit date and remain unconverted if the company never raises additional capital or is acquired. At a founder's death, the SAFE passes into the estate and must be valued, typically at a significant discount because the conversion is speculative. The executor may attempt to sell the SAFE on secondary markets but will likely receive minimal proceeds. Valuing SAFEs for estate tax purposes requires an independent appraisal and specialized judgment about the probability of conversion.
How Afterpath Helps
Afterpath's equity tracker captures stock options, SAFEs, and illiquid secondary market positions, documenting vesting schedules, acceleration provisions, and post-death exercise rights. This prevents valuable options from lapsing due to missed deadlines and ensures executors understand the true value of founder equity at death.
Learn more at Afterpath Pro or join the waitlist for early access.
Related Reading
Explore related guidance on startup equity and estate valuation:
For Professionals
Streamline Your Estate Practice
Join professionals using Afterpath to manage estate settlements more efficiently. Early access is open.
Save My Spot